Total voting rights

| Source: Novo Nordisk A/S Novo Nordisk A/S

In accordance with Section 6 of the Danish Statutory Order on Issuers Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk as per the end of the month where changes have occurred.
 
Referring to Stock Exchange Announcement no 16/2007 dated 19 June 2007, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk as per 29 June 2007.
 
 
Number of shares (nominal value
DKK 2)
Nominal value (DKK)
Number of votes
 
A shares
 
     
53,743,600
 

107,487,200
 

1,074,872,000
 
B shares
 
  
269,736,400
 

539,472,800
 
  
539,472,800
 
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
 
For further information please contact:
 
Stock Exchange Announcement no 18 / 2007